New NeOnc (NASDAQ: NTHI) director is CEO's niece
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
NeOnc Technologies Holdings, Inc. reported a change on its Board of Directors. On June 27, 2026, Class II director Ming-Fu (Alan) Chiang, M.D., Ph.D., MBA, resigned from the Board and from the Scientific Advisory Board, and the company states his resignation was not due to any disagreement over operations, policies, or practices.
On July 1, 2026, the Board elected Nasim Shomali as a Class II director to serve until the 2027 annual meeting of stockholders. She previously served as a Strategy Executive at Accenture from April 2013 to April 2026, advising large companies on enterprise strategy and transformation. The company notes there is no arrangement under which she was selected, and discloses that Shomali is the niece of President, Chief Executive Officer and Executive Chairman Amir Heshmatpour.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Chiang resignation date: June 27, 2026
Shomali election date: July 1, 2026
Term end reference: 2027 annual meeting
+1 more
4 metrics
Chiang resignation date
June 27, 2026
Effective date of director and Scientific Advisory Board resignation
Shomali election date
July 1, 2026
Effective date of Nasim Shomali’s appointment as Class II director
Term end reference
2027 annual meeting
End of current term for Shomali as Class II director
Accenture tenure period
April 2013–April 2026
Duration of Shomali’s Strategy Executive role at Accenture
Key Terms
Class II director, Scientific Advisory Board, Emerging growth company, annual meeting of stockholders
4 terms
Class II director financial
"a Class II director, notified NeOnc Technologies Holdings, Inc."
A class II director is a member of a company’s board who belongs to one of several staggered groups of directors, each group standing for election in different years. For investors, this matters because staggered terms slow wholesale board turnover—like rotating members of a neighborhood committee—making sudden changes in control or strategy harder and affecting how quickly shareholders can influence corporate direction.
Scientific Advisory Board financial
"In connection with his resignation, Dr. Chiang also resigned from the Company’s Scientific Advisory Board."
A scientific advisory board is a group of independent experts—often scientists, clinicians or technical specialists—who give a company guidance on its research, product development and regulatory strategy. For investors, their role is like an external quality check: credible experts can reduce technical risk, improve the chance of regulatory approval or successful products, and boost confidence that management’s science claims are realistic and well-directed.
Emerging growth company regulatory
"Emerging growth company On June 27, 2026, Ming-Fu"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
annual meeting of stockholders financial
"to serve as a Class II director until the Company’s 2027 annual meeting of stockholders."
FAQ
What board change did NeOnc Technologies (NTHI) disclose?
NeOnc Technologies reported that Class II director Ming-Fu (Alan) Chiang resigned from the Board and Scientific Advisory Board, effective June 27, 2026. The company stated his departure was not due to any disagreement regarding operations, policies, or practices.
Who replaced Dr. Chiang on NeOnc Technologies' board?
The Board elected Nasim Shomali as a Class II director effective July 1, 2026, to serve until the 2027 annual meeting. She brings extensive strategy experience from her role as a Strategy Executive at Accenture between April 2013 and April 2026.
What is Nasim Shomali’s professional background before joining NTHI’s board?
From April 2013 to April 2026, Nasim Shomali served as a Strategy Executive at Accenture. She advised Fortune 20 executives on enterprise strategy, operating-model development, product redesign, market expansion, and efficiency initiatives across global software, platform, technology, and sustainability portfolios.
Does the new NeOnc director have any relationship with company leadership?
Yes. The filing states that new director Nasim Shomali is the niece of Amir Heshmatpour, who serves as NeOnc’s President, Chief Executive Officer and Executive Chairman. The company also notes there was no arrangement or understanding under which she was selected.
How long will Nasim Shomali serve on NeOnc Technologies' board?
Nasim Shomali was elected as a Class II director and will serve until NeOnc Technologies’ 2027 annual meeting of stockholders. Her future service beyond that meeting would depend on re-election by stockholders at that time, consistent with standard board classification.
Did NeOnc indicate any disputes behind Dr. Chiang’s resignation?
The company explicitly stated that Dr. Ming-Fu (Alan) Chiang’s resignation from the Board and Scientific Advisory Board was not the result of a disagreement with NeOnc on any matter relating to its operations, policies, or practices, suggesting an orderly transition rather than a conflict.